Real-world clinical characteristics and outcomes of patients with locally advanced, unresectable esophageal/gastroesophageal junction cancer treated with definitive chemoradiotherapy in the United States community oncology setting
The results of this analysis emphasize an unmet need for more effective therapies for EC/GEJC patients to prevent disease recurrence and improve outcomes.
Authors
- S. Bordia
- Lisa Herms
- Adriana Valderrama (ORCID: https://orcid.org/0000-0003-4480-3879)
- Sujatha Nallapareddy
- Junxin Shi
- Helen Latimer
- Gregory Patton
- Karthik Ramakrishnan
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- AIR Worldwide (United States) (US)
- Rocky Mountain Cancer Centers (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.3389/fonc.2025.1679386
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00